Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
John F. Seymour,
Robert Marcus,
Andrew Davies,
Eve Gallop-Evans,
Andrew Grigg,
Andrew Haynes,
Michael Herold,
Thomas Illmer,
Herman Nilsson-Ehle,
Martin Sökler,
Ulrich Dünzinger,
Tina Nielsen,
Aino Launonen,
Wolfgang Hiddemann
Affiliations
John F. Seymour
Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia
Robert Marcus
Kings College Hospital, London, UK
Andrew Davies
Cancer Research UK Centre, University of Southampton, Southampton, UK
Eve Gallop-Evans
Velindre Cancer Centre, Cardiff, UK
Andrew Grigg
Austin Hospital, Melbourne, Victoria, NSW, Australia
Andrew Haynes
Nottingham University Hospitals NHS Trust, Nottingham, UK
Michael Herold
HELIOS-Klinikum Erfurt, Germany
Thomas Illmer
BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany
Herman Nilsson-Ehle
Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
